The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic
Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA < 50 copies/ml (PCR)
and CD4 levels > 400.